Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia Patients During Symptomatic Remission
NCT06021197Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing NMDAE with Placebo (2 arms). Primary endpoint: Change of cognitive function composite at 12 weeks. Started Oct 2023; status: recruiting.
02
Drugs
sodium benzoate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06021197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021197.